Very Conservative Balance SheetNear-zero debt and a negligible debt-to-equity position provide durable financial flexibility. This reduces solvency risk, supports investment or M&A optionality, and preserves capital allocation choices across economic cycles, benefitting operations and steady growth plans.

Strong Free Cash Flow ReboundA large rebound in free cash flow and materially higher coverage of net income indicate improving cash conversion. Sustainable FCF strengthens self-funding for capex, R&D, paydowns or shareholder returns and lowers reliance on external financing.

Steady Revenue Growth And High Gross MarginsConsistent top-line growth paired with gross margins north of 50% points to resilient product economics and pricing power. This supports operating leverage over time and provides a durable earnings base even if growth moderates.

Bears Say

Margin CompressionMaterial margin erosion in a single year signals cost pressures or pricing squeeze that could persist. Lower EBITDA and net margins reduce reinvestment capacity and return on invested capital, making profitability more sensitive to input cost or competitive dynamics.

Variable Cash ConversionOperating cash below net income and prior volatility suggest working-capital sensitivity in the business. Persistent variability can strain liquidity during growth phases, complicate forecasting, and reduce the reliability of reported earnings as a cash proxy.

ROE Has ModeratedA step-down in ROE indicates returns are not rising with the expanding equity base, signaling either slower profit growth or increased capital intensity. If sustained, lower ROE could limit shareholder value creation relative to peers.

Lincoln Pharmaceuticals Ltd News

Lincoln Pharmaceuticals Ltd Announces AGM Voting Results

Lincoln Pharmaceuticals Ltd ( ($IN:LINCOLN) ) has provided an update. Lincoln Pharmaceuticals Ltd announced the voting results of...

5M ago

Lincoln Pharmaceuticals Ltd Reports Successful AGM with Strong Shareholder Support

The latest update is out from Lincoln Pharmaceuticals Ltd ( ($IN:LINCOLN) ). Lincoln Pharmaceuticals Ltd successfully held its...

5M ago

Lincoln Pharmaceuticals Announces Key Leadership Re-Appointments

Lincoln Pharmaceuticals Ltd ( ($IN:LINCOLN) ) has shared an update. Lincoln Pharmaceuticals Ltd has announced changes in its...

7M ago

Lincoln Pharmaceuticals Appoints New Secretarial Auditor

An announcement from Lincoln Pharmaceuticals Ltd ( ($IN:LINCOLN) ) is now available. Lincoln Pharmaceuticals Ltd has announced the...

7M ago

LINCOLN FAQ

What was Lincoln Pharmaceuticals Ltd’s price range in the past 12 months?

Lincoln Pharmaceuticals Ltd lowest stock price was ₹439.95 and its highest was ₹679.45 in the past 12 months.

What is Lincoln Pharmaceuticals Ltd’s market cap?

Lincoln Pharmaceuticals Ltd’s market cap is ₹12.35B.

When is Lincoln Pharmaceuticals Ltd’s upcoming earnings report date?

Lincoln Pharmaceuticals Ltd’s upcoming earnings report date is May 21, 2026 which is in 82 days.

How were Lincoln Pharmaceuticals Ltd’s earnings last quarter?

Lincoln Pharmaceuticals Ltd released its earnings results on Feb 12, 2026. The company reported ₹14.279 earnings per share for the quarter, beating the consensus estimate of N/A by ₹14.279.

Is Lincoln Pharmaceuticals Ltd overvalued?

According to Wall Street analysts Lincoln Pharmaceuticals Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lincoln Pharmaceuticals Ltd pay dividends?

Lincoln Pharmaceuticals Ltd pays a Annually dividend of ₹1.8 which represents an annual dividend yield of 0.37%. See more information on Lincoln Pharmaceuticals Ltd dividends here

What is Lincoln Pharmaceuticals Ltd’s EPS estimate?

Lincoln Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lincoln Pharmaceuticals Ltd have?

Lincoln Pharmaceuticals Ltd has 20,029,728 shares outstanding.

What happened to Lincoln Pharmaceuticals Ltd’s price movement after its last earnings report?

Lincoln Pharmaceuticals Ltd reported an EPS of ₹14.279 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.516%.

Which hedge fund is a major shareholder of Lincoln Pharmaceuticals Ltd?

Currently, no hedge funds are holding shares in IN:LINCOLN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.